Navigation Links
Experimental vaccine for shingles is effective

Researchers have discovered a newer form of chicken pox vaccine to// effectively control the painful condition called shingles.

Shingles (also known as herpes zoster) is the condition that gets symptoms of rashes or blisters on the skin, along with sensations of burning pain, tingling, and numbness on the area. There may be fever with chills, headache or upset stomach. The infection is somewhat like chicken pox and is caused by the same virus varicella-zoster. Anyone who had chicken pox once is at a risk. Scientists say that the chicken pox virus moves into the nervous system after the attack, and reactivates as shingles.

The new vaccine called zoster vaccine is a more potent version of the chicken pox vaccine that’s available for the children. This vaccine contains live and weak form of the varicella-zoster virus that causes chicken pox. The vaccine had been able to prevent the occurrence of shingles for half the people who received it, and reduced significantly the severity and complications of the disease in most of the vaccinated people.

Shingles is a condition that keeps on affecting people and affects the elderly people more severely. The new vaccine for adults will now be able to bring relief to all people who have been suffering from the disease.

The research will be published in the new edition of New England Journal of Medicine.
'"/>




Page: 1

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental SARS Vaccine
4. Experimental Blood Test May Spot Heart Attack Risk, Study Says
5. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
6. Protection against HIV and Herpes is possible with the Experimental Microbicide
7. Experimental Therapy Effective Against Malignant Melanoma in Horses
8. Experimental Alzheimer’s Drug curbs the disease in mic
9. New Guidelines to Be Laid While Testing Experimental Drugs
10. Experimental Drug Deals Effectively with Prostate Cancer Cells
11. Experimental Drug Causes Cytokine Storm
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... (NYSE, TASE: PRGO) today announced it has received final approval ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... oral solution (syrup), 5 mg/1.5 mg per 5 mL is ... children 6 years of age and older. Annual sales for ...   ...
Breaking Medicine Technology: